Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 11, November, p. 1569–1570

doi: 10.17219/acem/94158

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Neglecting regression to the mean continues to lead to unwarranted conclusions: Letter regarding “The magnitude of weight loss induced by metformin is independently associated with BMI at baseline in newly diagnosed type 2 diabetes: Post-hoc analysis from data of a phase IV open-labeled trial”

Bridget A. Hannon1,A,D,E,F, Diana M. Thomas2,D,E,F, Cynthia O. Siu3,E,F, David B. Allison4,A,D,E,F

1 Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, USA

2 Department of Mathematical Sciences, United States Military Academy, West Point, USA

3 COS & Associates Ltd., Hong Kong

4 Indiana University School of Public Health-Bloomington, USA

Abstract

As the prevalence of type 2 diabetes mellitus and obesity increases worldwide, scientifically rigorous research is needed in this field to determine effective interventions for the prevention and treatment of these chronic diseases. In a recent study published in this journal, Zhou et al. conclude that metformin, a drug used for treatment of type 2 diabetes mellitus, can be used effectively for weight loss, and that this effect is even more pronounced in individuals who weigh more at baseline. Unfortunately, we believe these results to be due to the regression to the mean (RTM) phenomenon, which weakens the causal inference proposed in this study. The conclusions of Zhou et al. that metformin is an effective strategy for weight loss in individuals with type 2 diabetes mellitus are not substantiated due to the lack of a control group and failure to consider other factors that may have confounded these results.

Key words

statistics, metformin, body weight loss

References (8)

  1. Zhou L, Cai X, Yang W, Han X, Ji L. The magnitude of weight loss induced by metformin is independently associated with BMI at baseline in newly diagnosed type 2 diabetes: Post-hoc analysis from data of a phase IV open-labeled trial. Adv Clin Exp Med. 2017;26(4):671–677. doi:10.17219/acem/63025
  2. Ellenberg J. How Not to Be Wrong: The Power of Mathematical Thinking. New York, NY: The Penguin Press; 2014.
  3. Bland JM, Altman DG. Regression towards the mean. BMJ. 1994;308:1499. doi: 10.1136/bmj.308.6942.1499
  4. George BJ, Beasley TM, Brown AW, et al. Common scientific and statistical errors in obesity research. Obesity. 2016:24(4):781–790. doi:10.1002/oby.21449
  5. Skinner AC, Goldsby TU, Allison DB. Regression to the mean: A commonly overlooked and misunderstood factor leading to unjustified conclusions in pediatric obesity research. Child Obes. 2016;12(2):155–158. doi:10.1089/chi.2015.0222
  6. Skinner AC, Heymsfield SB, Pietrobelli A, Faith MS, Allison DB. Ignoring regression to the mean leads to unsupported conclusions about obesity [letter]. Int J Behav Nutr Phys Act. 2015;12:56.
  7. Allison DB, Loebel AD, Lombardo I, Romano SJ, Siu CO. Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean? Psychiatry Res. 2009;170(2–3):172–176. doi:10.1016/j.psychres.2008.10.007
  8. Thompson, B. Why won’t stepwise methods die? Meas Eval Couns Dev. 1989:21(4):146–148.
© Wroclaw Medical University